Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-11-09 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Agreement with Eccogene for clinical stage GLP-1RA
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' header and contains a date (09 November 2023), indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS) of the London Stock Exchange. The content describes a significant corporate event: AstraZeneca licensing a novel drug candidate (ECC5004) from Eccogene, including financial terms ($185m upfront, up to $1.825bn in milestones). This type of announcement—a material business development or transaction—is typically released via RNS. Since it is a general regulatory announcement that doesn't fit perfectly into specific categories like M&A (TAR) or Capital Change (CAP), and it is clearly an official regulatory news service release, the most appropriate general classification is Regulatory Filings (RNS). The document length (6540 chars) is substantial enough that it is the primary announcement itself, not just a notice about an attachment (which would suggest RPA).
2023-11-09 English
9M and Q3 2023 results
Earnings Release Classification · 100% confidence The document text begins with 'National Storage Mechanism | Additional information RNS Number : 8657S AstraZeneca PLC 09 November 2023' and presents detailed financial summaries for '9M and Q3 2023 results', including revenue, EPS, margin analysis, guidance updates, and pipeline milestones. The presence of '9M' (Nine Months) and 'Q3' (Third Quarter) strongly indicates a comprehensive report covering a period shorter than a full year, which aligns with an Interim/Quarterly Report (IR). Although it contains earnings highlights, the depth of financial tables (Table 1, Table 2) and pipeline details suggests it is more than just a brief Earnings Release (ER). It is not a short announcement linking to a report, as the full content appears to be present, making it the report itself, specifically the quarterly/interim report. 9M 2023
2023-11-09 English
TOTAL VOTING RIGHTS
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of 31 October 2023, providing details on issued share capital and voting rights. The document is relatively short (3169 characters) and primarily serves as a notification of voting rights rather than a full report or detailed financial disclosure. It does not contain financial statements, management discussion, or detailed analysis. The document is an official regulatory announcement related to shareholder voting rights and capital structure, fitting the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-11-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification released via RNS (London Stock Exchange news service) on November 1, 2023. It explicitly states it is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. The content details the total number of issued shares with voting rights (1,549,914,516) as of October 31, 2023, which is used by shareholders as the denominator for determining notification requirements under transparency rules. This specific type of regulatory disclosure regarding the total voting rights capital structure is best classified under 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it directly relates to the mechanics of shareholder voting rights calculation, although it is a routine update rather than a result of a specific vote. Given the options, DVA is the most precise fit for a 'Voting rights and capital' notification under transparency rules, even if it's not a final vote tally. However, since the core content is a routine regulatory update about the total number of voting rights, and it is distributed via RNS, it could also be considered a general Regulatory Filing (RNS). Comparing DVA (Declaration of Voting Results & Voting Rights Announcements) and RNS (Regulatory Filings - fallback), DVA is more specific to the subject matter (voting rights denominator). I will select DVA as the primary classification.
2023-11-01 English
ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It announces a collaboration and investment agreement with Cellectis, detailing the terms of the deal, financial considerations, and strategic intent. The document does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is primarily an announcement of a capital investment and collaboration agreement, which fits the category of Capital/Financing Update. The length of the document (7505 characters) and the detailed description of the investment and collaboration terms support this classification. Therefore, the appropriate filing type is Capital/Financing Update (CAP).
2023-11-01 English
AstraZeneca cell & gene therapy deal w/ Cellectis
M&A Activity Classification · 99% confidence The document is a formal announcement released via RNS (Regulatory News Service) on November 1, 2023, detailing a collaboration and investment agreement between AstraZeneca and Cellectis. It discusses strategic partnerships, financial considerations (payments, equity investment), and future development plans. This type of announcement, which details significant corporate transactions, strategic moves, or material non-public information released through an official regulatory wire service, fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific financial report (10-K, IR, ER), a management discussion (MDA), or a proxy statement (DEF 14A). While it contains financial elements, its primary function is a broad corporate update disseminated via the regulatory feed.
2023-11-01 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.